Stocks and Investing Stocks and Investing
Fri, April 30, 2021

David Lebovitz Maintained (BPMC) at Hold with Decreased Target to $101 on, Apr 30th, 2021


Published on 2024-10-27 16:28:50 - WOPRAI, David Lebovitz
  Print publication without navigation


David Lebovitz of Morgan Stanley, Maintained "Blueprint Medicines Corporation" (BPMC) at Hold with Decreased Target from $105 to $101 on, Apr 30th, 2021.

David has made no other calls on BPMC in the last 4 months.



There are 5 other peers that have a rating on BPMC. Out of the 5 peers that are also analyzing BPMC, 2 agree with David's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Brad Canino of "Credit Suisse" Initiated at Hold and Held Target at $100 on, Wednesday, March 31st, 2021
  • Peter Lawson of "Barclays" Maintained at Hold with Increased Target to $95 on, Thursday, February 18th, 2021


These are the ratings of the 3 analyists that currently disagree with David


  • Michael Schmitz of "Guggenheim" Maintained at Strong Buy with Decreased Target to $110 on, Thursday, April 29th, 2021
  • Liana Moussatos of "Wedbush" Maintained at Buy with Increased Target to $136 on, Tuesday, April 13th, 2021
  • Andrew Berens of "SVB Leerink" Maintained at Buy with Increased Target to $127 on, Tuesday, January 12th, 2021
Contributing Sources